Document:

Exhibit 10.1

 

 

NON-EXCLUSIVE CONSULTING AGREEMENT

 

NON-EXCLUSIVE CONSULTING
AGREEMENT (this “Agreement”), dated as of October 15, 2015 (the “Commencement Date”),
by and between, Calmare Therapeutics Incorporated, a Delaware corporation (referred to herein, collectively with its affiliates
and subsidiaries, as “CTI”), having its principal place of business at 1375 Kings Highway East, Suite
400, Fairfield, CT 06824, and VADM Robert T. Conway, Jr., U.S. Navy, (Ret), the Consultant as so described in Appendix 1 hereto
(the “Consultant”).

 

WITNESSETH

 

WHEREAS, CTI is engaged in the business
of selling, distributing and licensing pain management equipment, and is located in Fairfield, Connecticut;

 

WHEREAS, Consultant has skills,
contacts, in-roads and experience from his career in dealing with the U.S. Department of Defense, Military, and similar organizations
that are synergistic with CTI’s business, and is willing to help further CTI’s business for certain compensation;

 

WHEREAS,
Consultant is an independent contractor and a related-party member of CTI’s Board of Directors for the purpose of
carrying out the aforementioned tasks; and

 

WHEREAS, CTI and Consultant are desirous
of entering into this annual consulting agreement, commencing monthly, in accordance with the terms and conditions hereinafter
set forth.

 

NOW, THEREFORE, the parties hereto do hereby
agree as follows:

 

1.            Integration. The terms and
conditions set forth in the preamble and recitals above are hereby fully integrated into and made a part of this Agreement.

 

2.            Role of Consultant. CTI acknowledges and agrees that
Consultant, acting primarily as a consultant on a non-exclusive basis, shall have no authority to enter into any binding commitments
or negotiations in connection with any contract on CTI’s behalf without approval and written authorization by CTI.

 

Notwithstanding
the foregoing, Consultant shall have the right to:

 

		a.	introduce CTI or any of its representatives to any and all:

 

		i.	persons, companies, organizations, et al., that can help further
Calmare Pain Mitigation Therapy (“Calmare PMT”) and/or CTI; provided, however, that after such introduction,
Consultant shall have no continuing obligation in the negotiations or relationship between CTI and such parties.

 

		ii.	potential sales prospects, Government-related or otherwise.

 

		b.	advise CTI Management or any of its representatives with respect to those skills, talents and situation Consultant is
suited to be a value-add to the situation or potential transaction; provided, however, that after such introduction, Consultant
shall have no continuing obligation in the negotiations or relationship between CTI and such parties.

 

     

     

    

 

3.            Independent
Contractor. In all matters relating to this Agreement, Consultant shall be acting as an independent contractor. Neither
the Consultant nor employees or subcontractors of the Consultant, if any, are employees of CTI under the meaning or application
of any U.S. Federal or State Unemployment or Insurance Laws, Old Age Benefit Laws, Social Security Laws, any Workmen's Compensation,
or Industrial Laws and/or otherwise. Consultant agrees to assume all liabilities or obligations imposed by any one or more
of such laws with respect to employees or subcontractors of Consultant, if any, in the performance of this Agreement. Moreover,
Consultant shall not have any authority to assume or create any obligation, expressed or implied, on behalf of CTI, and Consultant
shall have no authority to represent CTI as agent, employee or in any other capacity than as hereinbefore set forth. Consultant
shall be solely responsible for filing all returns and paying any income, social security or other tax levied upon or determined
with respect to the payments made to Consultant pursuant to this Agreement. And in the event that Consultant is provided a CTI
business card, Consultant may only use the card in carrying out his or her obligations hereunder.

 

		4.	Consideration. CTI agrees to compensate Consultant as follows: 

 

		a.	Retainer Fee.
                                         There shall be a monthly retainer fee (the “Retainer”) of $7,500.00
                                         per month paid in cash, payable on the 15th of each month. 

 

		b.	Equity. In addition to the retainer fee, Consultant shall be issued five year warrants to
purchase 167,000 shares of common stock of the Corporation, immediately issued and vested, at a strike price of $.60 per share.

 

		c.	Expenses. All expenses shall be paid on the 15th
or 30th of each month, Pari-passu with CTI’s payroll cycle. All expenses
that exceed $1000.00, require prior approval.

 

5.            General. This Agreement shall: (i) contain the
entire understanding of the parties with respect to its subject matter, and no modification, amendment or waiver of any
provision hereof shall be valid unless in writing, signed by each of the parties hereto; (ii) be governed by and construed in accordance
with the laws of the State of New York, without regard to the conflicts of law provisions of such State; and (iii) be signed in
counterparts, any one of which will be deemed to be an original and all of which, when taken together, will constitute one and
the same agreement.

 

		a.	Delivery. All delivery of an executed counterpart of a signature page of this Agreement by telephone facsimile transmission
will be effective as delivery of a manually executed counterpart of this Agreement.

 

		b.	Headings. The paragraph headings contained herein are for convenience only and shall not
affect the construction of this Agreement.

 

6.            Term of the Agreement. This
Agreement shall become effective as of the Commencement Date and shall continue for one (1) calendar year, or until CTI and/or
Consultant delivers notice of termination to the other party, as so delineated herein (See Section 7, “Termination”
below).

 

		7.	Termination. This Agreement may be terminated as follows: 

 

		a.	If by CTI: 

 

		i.	Breach or default of any obligation of Consultant and including but not limited to “Confidentiality”
of this Agreement, and any other material obligation in this Agreement

 

		ii.	Any breach or default that is not cured within seven (7) days of written notice from the Company.

 

		b.	If by Consultant: 

 

		i.	Breach or default of any material obligation of Company, which breach or default is not cured within
fifteen (15) days of written notice from Consultant.

 

    2 

     

    

  

8.            Confidentiality.
During the term of this Agreement, and thereafter for a period of two (2) years, Consultant shall not, without
the prior written consent of Company, disclose to anyone any Confidential Information. “Confidential Information”
for the purposes of this Agreement shall include Company’s proprietary and confidential information such as, but not
limited to, customer lists, business plans, marketing plans, financial information, designs, drawing, specifications, models,
software, source codes and object codes. Confidential Information shall not include any information that:

 

		a.	is disclosed by Company without restriction

 

		b.	becomes publicly available through no act of Consultant

 

		c.	is rightfully received by Consultant from a third party

 

9.            Entire Contract. This Agreement
contains all the terms and conditions agreed upon by the Parties and constitutes the only agreement in force and effect
between the Parties relating to the subject matter herein.

 

10.          Titles.
The titles, if any, used to introduce the Articles of this Agreement are provided for convenience purposes only and
shall not be interpreted to alter the meaning of any Article.

 

11.           Notice. Any notice required
to be given or otherwise given pursuant to this Agreement shall be in writing and shall be hand delivered, mailed by certified
mail, return receipt requested or sent by recognized overnight courier service as follows:

 

If to CONSULTANT:

VADM Robert T. Conway, Jr., U.S. Navy, (Ret)

1910 So Ocean Blvd Apt 218

Delray Beach, FL 33483

Telephone: (202) 256-5540

Facsimile: ( )

Attn: VADM Robert T. Conway, Jr. U.S. Navy, (Ret)

 

If to CTI:

Calmare Therapeutics Incorporated

1375 Kings Highway East

Fairfield, CT 06824

Telephone: (203) 386-6400

Facsimile: (203) 386-5399

Attn: Conrad Mir, President & CEO

 

With copies to:

Szaferman, Lakind, Blumstein & Blader, P.C.

101 Grovers Mill Road, Second Floor

Lawrenceville, New Jersey 08648

Telephone: (609) 275-0400

Facsimile: (609) 275-4511

Attn: Gregg E. Jaclin, Esq.

 

12.           Severability.
If any provisions of this Agreement shall be invalid, illegal or unenforceable for any reason, the remaining terms
and provisions shall be unaffected thereby and shall continue in full force and effect.

 

    3 

     

    

 

IN WITNESS WHEREOF, the parties hereto have
duly executed this Agreement as of the date first above written.

 

	 	CALMARE THERAPEUTICS INCORPORATED
	 	 	 
	 	By:  	/s/ Conrad Mir
	 	 	Conrad Mir
	 	 	President & CEO
	 	 
	 	CONSULTANT
	 	 	 
	 	By: 	/s/ Robert T. Conway, Jr. 
	 	 	VADM Robert T. Conway, Jr., U.S. Navy, (Ret)

 

    4Form of Purchase Agreement

 Exhibit 10.1 

PURCHASE AGREEMENT 
 THIS
AGREEMENT is made as of the 2nd day of December, 2015, by and between Sunshine Bancorp, Inc. (the “Company”), a corporation organized under the laws of the State of Maryland, with its principal offices at 102 West Baker Street,
Plant City, Florida 33563 and the purchaser whose name and address is set forth on the signature page hereof (the “Purchaser”). 

IN CONSIDERATION of the mutual covenants contained in this Agreement, the Company and the Purchaser agree as follows: 

SECTION 1. Authorization of Sale of the Shares. Subject to the terms and conditions of this Agreement, the Company has authorized the
issuance and sale of up to 875,000 shares (the “Shares”) of common stock, $0.01 par value (the “Common Stock”), of the Company. 

SECTION 2. Agreement to Sell and Purchase the Shares. At the Closing (as defined in Section 3), the Company will, subject to the
terms of this Agreement, issue and sell to the Purchaser and the Purchaser will buy from the Company, upon the terms and conditions hereinafter set forth, the number of Shares (at the purchase price) set forth on the signature page attached hereto.
The Company proposes to enter into the same form of purchase agreement with certain other investors (the “Other Purchasers”) and expects to complete sales of the Shares to them. The Purchaser and the Other Purchasers are hereinafter
sometimes collectively referred to as the “Purchasers,” and this Agreement and the purchase agreements executed by the Other Purchasers are hereinafter sometimes collectively referred to as the “Agreements.” The term
“Placement Agent” shall mean Raymond James & Associates, Inc. 
 Notwithstanding the foregoing, nothing in this
Agreement shall be construed to permit or require the Purchaser to purchase a number of Shares that would cause the Purchaser, together with any other person whose Company securities would be aggregated with the Purchaser’s Company securities
for purposes of any banking regulation or law (or for purposes of any securities regulation or law or any NASDAQ rule), to (i) violate any banking regulation, (ii) file a prior notice under the Change in Bank Control Act (the “CIBC
Act”), or otherwise seek prior approval of any banking regulator, (iii) to become, or be required to register as, a savings and loan holding company or otherwise serve as a source of strength for the Company or any subsidiary or
(iv) cause the Purchaser, together with any other person whose Company securities would be aggregated with the Purchaser’s Company securities for purposes of any banking regulation or law (or for purposes of any securities regulation or
law or any NASDAQ rule), to collectively be deemed to own, control or have the power to vote securities which would represent more than 9.9% of any class of voting securities, or 25% of total equity, of the Company outstanding at such time, or 4.9%
of any class of voting securities of the Company outstanding at such time if such Purchaser was a bank holding company or savings and loan holding company. Clauses (i) through (iv) are referred to as the “Ownership
Limitations”. If, but for this sentence, the purchase of Shares at the Closing would otherwise cause the Purchaser to exceed any Ownership Limitation, then the number of Shares to be purchased by the Purchaser hereunder at the Closing shall
be automatically reduced by the minimum amount necessary to ensure that no Ownership Limitation is exceeded by the Purchaser at Closing (in which case the Purchaser’s aggregate purchase price shall be proportionately reduced). 

 SECTION 3. Delivery of the Shares at the Closing. The completion of the purchase and sale
of the Shares (the “Closing”) shall occur at the offices of Troutman Sanders LLP, 600 Peachtree Street NE, Suite 5200, Atlanta, Georgia 30308 as soon as practicable and as agreed to by the parties hereto, within three business days
following the execution of the Agreements, or on such later date or at such different location as the parties shall agree in writing, but not prior to the date that the conditions for Closing set forth below have been satisfied or waived by the
appropriate party (the “Closing Date”). 
 At the Closing, the Purchaser shall deliver, in immediately available funds, the full amount of
the purchase price for the Shares being purchased hereunder by wire transfer to an account designated by the Company and the Company shall deliver to the Purchaser (or its designated custodian per its delivery instructions) one or more stock
certificates registered in the name of the Purchaser, or in such nominee name(s) as designated by the Purchaser in writing, representing the number of Shares set forth on the signature page attached hereto and bearing an appropriate legend referring
to the fact that the Shares were sold in reliance upon the exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof and Rule 506 thereunder. The
Company will promptly substitute one or more replacement certificates without the legend at such time as the registration statement filed by the Company pursuant to Section 7.1 hereof (the “Registration Statement”) becomes
effective. The name(s) in which the stock certificates are to be registered are set forth in the Securities Certificate Questionnaire attached hereto as Appendix I. Notwithstanding anything to the contrary set forth herein, the Purchaser shall not
be required to send its payment for its Shares until its designated custodian, Troutman Sanders LLP, confirms receipt of a copy of the irrevocable instructions from the Company to Computershare Inc., in its capacity as transfer agent for the Common
Stock (“Computershare”), instructing Computershare to deliver to the Purchaser on an expedited basis certificates representing its Shares; provided, however, that in the event that the Closing does not occur or the Purchaser fails
to pay the full purchase price for its Shares, then the Purchaser shall promptly cause the original certificates representing the corresponding Shares to be returned to the Company for cancellation. 

3.1 Conditions Precedent for all Parties. The Parties obligation to consummate the transactions contemplated herein shall be subject
to the following conditions any one or more of which may be waived by the Parties jointly: 
 (i) No governmental agency or body, nor any
federal or state court of competent jurisdiction or arbitrator shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, executive order, decree, judgment, injunction or arbitration award or other order (in each
case, whether temporary, preliminary or permanent) which is in effect and prevents or prohibits consummation of the transactions contemplated by this Agreement and no litigation or court or administrative proceeding shall be pending against any of
the Parties by any governmental agency or body or third party seeking to restrain, enjoin, prevent or otherwise prohibit consummation of the transactions contemplated hereby. 

  
 2 

 3.2 Conditions Precedent for the Company. The Company’s obligation to complete the
purchase and sale of the Shares and deliver such stock certificates to the Purchaser at the Closing shall be subject to the following conditions, any one or more of which may be waived by the Company: (a) following the Purchaser’s receipt
of its Shares, receipt by the Company of same-day funds in the full amount of the purchase price for the Shares being purchased hereunder; (b) concurrent completion of the purchases and sales under the Agreements with the Other Purchasers; and
(c) the accuracy of the representations and warranties made by the Purchasers and the fulfillment of any and all undertakings of the Purchasers prior to the Closing. 

3.3 Conditions Precedent for the Purchaser. The Purchaser’s obligation to accept delivery of such stock certificates and to pay
for the Shares evidenced thereby shall be subject to the following conditions: 
 (i) each of the representations and warranties of the
Company made herein shall be accurate in all material respects (except to the extent that any of such representations and warranties is qualified by materiality or Material Adverse Effect, in such case, such representations and warranties shall be
accurate in all respects) as of the Closing Date; 
 (ii) the delivery to the Purchaser by counsel to the Company of a legal opinion to
Purchaser in a form reasonably satisfactory to counsel to the Purchaser; 
 (iii) receipt by the Purchaser of a certificate executed by the
chief executive officer and the chief financial or accounting officer of the Company, dated as of the Closing Date, to the effect that the representations and warranties of the Company set forth herein are true and correct in all material respects
(except to the extent that any of such representations and warranties is qualified by materiality or Material Adverse Effect, in such case, such representations and warranties shall be accurate in all respects) as of the date of this Agreement and
as of such Closing Date and that the Company has complied in all material respects with all the agreements and satisfied all the conditions herein on its part to be performed or satisfied on or prior to such Closing Date; 

(iv) the fulfillment in all material respects of those undertakings of the Company to be fulfilled prior to Closing; 

(v) The Common Stock (i) shall be designated for listing and quotation on NASDAQ and (ii) shall not have been suspended, as of the
Closing Date, by the Commission or NASDAQ from trading on NASDAQ nor shall suspension by the Commission or NASDAQ have been threatened, as of the Closing Date, either (A) in writing by the Commission or NASDAQ or (B) by falling below the
minimum listing maintenance requirements of NASDAQ; 
 (vi) The purchase of Shares by the Purchaser shall not cause Purchaser to exceed any
Ownership Limitation; and 
 (vii) Since the date hereof, there shall not be any action taken, or any law, rule or regulation enacted,
entered, enforced or deemed applicable to the Company or its subsidiaries, the Purchaser (or its affiliates) or the transactions contemplated by this Agreement, by any Bank Regulatory Authorities which imposes any restriction or condition on the
Company or its 

  
 3 

 
subsidiaries or the Purchaser or any of its affiliates (other than such restrictions as are described in any passivity or anti-association commitments, as may be amended from time to time,
entered into by the Purchaser) which is materially and unreasonably burdensome on the Company’s business following the Closing or on the Purchaser (or any of its affiliates) or would reduce the economic benefits of the transactions contemplated
by this Agreement to the Purchaser to such a degree that the Purchaser would not have entered into this Agreement had such condition or restriction been known to it on the date hereof (any such condition or restriction, a “Burdensome
Condition”), and, for the avoidance of doubt, any requirements to disclose the identities of limited partners, shareholders or non-managing members of the Purchaser or its affiliates or its investment advisers, other than those that are
purchasing Common Stock directly, shall be deemed a Burdensome Condition unless otherwise determined by the Purchaser in its sole discretion. 

SECTION 4. Representations, Warranties and Covenants of the Company. The Company hereby represents and warrants to, and covenants
with, the Purchaser as follows: 
 4.1 Organization and Qualification. The Company is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of Maryland and the Company is qualified to do business as a foreign corporation in each jurisdiction in which qualification is required, except where failure to so qualify would not have a
Material Adverse Effect (as defined herein). The subsidiaries listed on Exhibit B hereto (the “Significant Subsidiaries”) are the Company’s only “significant subsidiaries,” as such term is defined in Rule 405 of the
Securities Act and the rules and regulations promulgated thereunder (the “Securities Act Rules and Regulations”). Each of the Significant Subsidiaries is a direct or indirect wholly owned subsidiary of the Company. Each of the
Significant Subsidiaries is duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation and is qualified to do business as a foreign corporation in each jurisdiction in which qualification is required,
except where failure to so qualify would not have a Material Adverse Effect (as defined below). 
 4.2 Reporting Company; Form S-3. The Company is not an “ineligible issuer” (as defined in Rule 405 promulgated under the Securities Act) and is eligible to register the Shares for resale by the Purchaser on a
registration statement on Form S-3 under the Securities Act. The Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and
has filed all reports required thereby to be filed since May 14, 2014 (all such reports made on or prior to the date hereof, the “SEC Filings”) on a timely basis. To the Company’s Knowledge, there exist no facts or
circumstances (including without limitation any required approvals or waivers or any circumstances that may delay or prevent the obtaining of accountant’s consents) that reasonably could be expected to prohibit or materially delay the
preparation and filing of a registration statement on Form S-3 that will be available for the resale of the Shares by the Purchaser. As used in this Agreement “Knowledge” with respect to
either the Company or one of its subsidiaries constitutes actual knowledge of such entity’s executive officers. 
 4.3 Authorized
Capital Stock. The Company has duly authorized and validly issued outstanding capitalization as set forth on Schedule 4.3. The issued and 

  
 4 

 
outstanding shares of the Company’s Common Stock have been duly authorized and validly issued, are fully paid and nonassessable, have been issued in compliance with all federal and state
securities laws, were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities, and conform in all material respects to the description thereof contained in the SEC Filings. Except as
disclosed in the SEC Filings, the Investor Presentation, dated November 2015, Schedule 4.3 hereto or in this Agreement (including all exhibits, supplements and amendments thereto and all information incorporated by reference therein, the
“Disclosure Materials”), the Company does not have outstanding any options to purchase, or any preemptive rights or other rights to subscribe for or to purchase, any securities or obligations convertible into, or any contracts or
commitments to issue or sell, shares of its capital stock or any such options, rights, convertible securities or obligations. With respect to each of the Significant Subsidiaries (i) all the issued and outstanding shares of each Significant
Subsidiary’s capital stock have been duly authorized and validly issued, are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, were not issued in violation of or subject to any preemptive
rights or other rights to subscribe for or purchase securities, and (ii) there are no outstanding options to purchase, or any preemptive rights or other rights to subscribe for or to purchase, any securities or obligations convertible into, or
any contracts or commitments to issue or sell, shares of such Significant Subsidiary’s capital stock or any such options, rights, convertible securities or obligations. There are no securities or instruments issued by or to which the Company is
a party containing anti-dilution or similar provisions that will be triggered by the issuance of the Shares. 
 4.4 Issuance, Sale and
Delivery of the Shares. The Shares have been duly authorized and, when issued, delivered and paid for in the manner set forth in this Agreement, will be validly issued, fully paid and nonassessable and free and clear of all pledges, liens,
restrictions and encumbrances (other than restrictions on transfer under state and/or federal securities laws), and will conform in all material respects to the description thereof set forth in the Incorporated Documents. No preemptive rights or
other rights to subscribe for or purchase any shares of Common Stock of the Company exist with respect to the issuance and sale of the Shares by the Company pursuant to this Agreement. No stockholder of the Company has any right (which has not been
waived or has not expired by reason of lapse of time following notification of the Company’s intention to file the Registration Statement) to require the Company to register the sale of any capital stock owned by such stockholder under the
Registration Statement. No further approval or authority of the stockholders or the Board of Directors of the Company will be required for the issuance and sale of the Shares to be sold by the Company as contemplated herein. 

4.5 Due Execution, Delivery and Performance of this Agreement. The Company has full legal right, corporate power and authority to
enter into the Agreements and perform the transactions contemplated hereby and thereby. Each of the Agreements has been duly authorized, executed and delivered by the Company. Each of the Agreements constitutes a legal, valid and binding agreement
of the Company, enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, conservatorship and supervisory powers of Bank Regulatory
Authorities generally, or other laws of general application relating to or affecting the enforcement of creditors’ rights and the application of equitable principles relating to the availability of remedies, and except as rights to indemnity or
contribution, including but 

  
 5 

 
not limited to, indemnification provisions set forth in Section 7.3 of this Agreement may be limited by federal or state securities law or the public policy underlying such laws. The
execution, delivery and performance of the Agreements by the Company and the consummation of the transactions herein and therein contemplated will not violate any provision of the articles of incorporation or bylaws of the Company or any
organizational documents of any Significant Subsidiary and will not result in the creation of any lien, charge, security interest or encumbrance upon any assets of the Company or any Significant Subsidiary pursuant to the terms or provisions of, and
will not conflict with, result in the breach or violation of, or constitute, either by itself or upon notice or the passage of time or both, a default under (A) any agreement, mortgage, deed of trust, lease, franchise, license, indenture,
permit or other instrument to which the Company or any Significant Subsidiary is a party or by which the Company or any Significant Subsidiary or their respective properties may be bound or affected and in each case that would have a Material
Adverse Effect or (B) any statute or any authorization, judgment, decree, order, rule or regulation of any court or any regulatory body, administrative agency or other governmental agency or body applicable to the Company or any Significant
Subsidiary or any of their respective properties. No consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental agency or body is required for the execution and delivery of this
Agreement or the consummation of the transactions contemplated by this Agreement, except for compliance with the Blue Sky laws and federal securities laws applicable to the offering of the Shares. For the purposes of this Agreement the term
“Material Adverse Effect” shall mean a material adverse effect on the financial condition, business, prospects or results of operations, taken as a whole, of the Company and its subsidiaries, taken together, other than an adverse
change or effect resulting from: (i) changes adversely affecting the U.S. economy or the banking or financial services industry generally; (ii) any change in applicable laws, rules, or regulations or the interpretation thereof;
(iii) any change in U.S. generally accepted accounting principles; (iv) an earthquake or other natural disaster; (v) the commencement, continuation or escalation of a war, material armed hostilities or other material international or
national calamity or act of terrorism directly or indirectly involving the United States of America; (vi) the announcement or pendency of this Agreement or the transactions contemplated thereby or hereby or (vii) the taking by parties of
any action contemplated or required by this Agreement. 
 4.6 Accountants. Hacker, Johnson & Smith PA, which has expressed
its opinion with respect to the consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which is included in the Disclosure
Materials, are registered independent public accountants as required by the Securities Act and the Securities Act Rules and Regulations and by the rules of the Public Accounting Oversight Board. 

4.7 No Defaults or Consents. Neither the execution, delivery and performance of the Agreements by the Company nor the consummation of
any of the transactions contemplated hereby or thereby (including, without limitation, the issuance and sale by the Company of the Shares) (A) will give rise to a right to terminate or accelerate the due date of any payment due under, or
conflict with or result in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under this Agreement, except such defaults that individually or in the
aggregate would not cause a Material Adverse Effect, or (B) will require any consent or waiver under, or result in 

  
 6 

 
the execution or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or its subsidiaries pursuant to the terms of, any indenture, mortgage, deed of trust or
other agreement or instrument to which the Company or any of its subsidiaries is a party or by which either the Company or its subsidiaries or any of their properties or businesses is bound, or any franchise, license, permit, judgment, decree,
order, statute, rule or regulation applicable to the Company or any Significant Subsidiary, except for such consents or waivers which have already been obtained and are in full force and effect. 

4.8 Contracts. The material contracts to which the Company is a party have been duly and validly authorized, executed and delivered by
the Company and constitute the legal, valid and binding agreements of the Company, enforceable by and against it in accordance with their respective terms, except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, conservatorship and supervisory powers of Bank Regulatory Authorities generally, or other similar laws relating to enforcement of creditors’ rights generally, and general equitable principles relating to the
availability of remedies, and except as rights to indemnity or contribution may be limited by federal or state securities laws and the public policy underlying such laws. 

4.9 No Actions. There are no legal or governmental actions, suits or proceedings pending or, to the Company’s Knowledge,
threatened against the Company or any Significant Subsidiary before or by any court, regulatory body or administrative agency or any other governmental agency or body, domestic, or foreign, which actions, suits or proceedings, individually or in the
aggregate, would reasonably be expected to have a Material Adverse Effect; and no labor disturbance by the employees of the Company exists or, to the Company’s Knowledge, is imminent, that would reasonably be expected to have a Material Adverse
Effect. Neither the Company nor any Significant Subsidiary is a party to or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or other governmental agency or body that would
reasonably be expected to have a Material Adverse Effect. 
 4.10 Properties. Each of the Company and its subsidiaries has good and
marketable title to all the properties and assets described as owned by it in the consolidated financial statements included in the SEC Filings, free and clear of all liens, mortgages, pledges, or encumbrances of any kind except (i) those, if
any, reflected in such consolidated financial statements, or (ii) those that are not material in amount and do not adversely affect the use made and proposed to be made of such property by the Company or its subsidiaries. Each of the Company
and its Significant Subsidiaries holds its leased properties under valid and binding leases and the Company and any Significant Subsidiary owns or leases all such properties as are necessary to its operations as now conducted. 

4.11 No Material Adverse Change; New Liabilities. Since September 30, 2015, (i) there has not occurred any event that has
had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect and (ii) except as set forth in the SEC Filings, the Company has not incurred any material liabilities (contingent or otherwise)
other than (A) trade payables, accrued expenses and other liabilities incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements
pursuant to generally accepted accounting principles or required to be disclosed in filings made with the Commission. 

  
 7 

 4.12 Intellectual Property. The Company and its subsidiaries own, is licensed or
otherwise possesses all rights to use, all patents, patent rights, inventions, know-how (including trade secrets and other unpatented or unpatentable or confidential information, systems, or procedures), trademarks, service marks, trade names,
copyrights and other intellectual property rights (collectively, the “Intellectual Property”) material and necessary for the conduct of its business as described in the SEC Filings, except where the failure to own, license or
otherwise possess all rights to use Intellectual Property would not reasonably be expected to have a Material Adverse Effect. No claims have been asserted against the Company or any subsidiary by any person with respect to the use of any such
Intellectual Property or challenging the validity of any such Intellectual Property, other than claims which would not reasonably be expected to have a Material Adverse Effect. 

4.13 Compliance. Neither the Company nor any of its subsidiaries has been advised, nor do any of them have any reason to believe, that
it is (i) not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in compliance would not have a Material Adverse Effect,
(ii) in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its subsidiaries under), nor has the Company or any of
its subsidiaries received written notice of a claim that it is in default under or that it is in violation of, any material contract (whether or not such default or violation has been waived), or (iii) in violation of any order of any court,
arbitrator or governmental body having jurisdiction over the Company, its subsidiaries or their respective properties or assets, except, in the case of clauses (ii) or (iii), where such failure or violation would not reasonably be expected to
have a Material Adverse Effect. 
 4.14 Taxes. The Company and each Significant Subsidiary has filed on a timely basis (giving
effect to extensions) all required federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and none of the Company or any of its subsidiaries has Knowledge of a tax deficiency that has been
or might be asserted or threatened against it that would reasonably be expected to have a Material Adverse Effect. All tax liabilities accrued through the date hereof have been adequately reserved for on the books of the Company. 

4.15 Transfer Taxes. On the Closing Date, all stock transfer or other similar taxes (other than income taxes) that are required to be
paid in connection with the sale and transfer of the Shares to be sold to the Purchaser hereunder will have been, fully paid or provided for by the Company and all laws imposing such taxes will have been fully complied with. 

4.16 Investment Company. The Company is not, and after application of the proceeds of the sale of Shares, will not be, an
“investment company” or an “affiliated person” of, or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment Company Act of 1940, as amended, and the rules and
regulations of the Securities and Exchange Commission (the “Commission”) promulgated thereunder. 

  
 8 

 4.17 Offering Materials. Each of the Company, its directors and officers has not
distributed and will not distribute prior to the Closing Date any offering material in connection with the offering and sale of the Shares other than the Disclosure Materials or any amendment or supplement thereto. The Company has not in the past
nor will it hereafter take any action independent of the Placement Agent to sell, offer for sale or solicit offers to buy any securities of the Company that could result in the initial sale of the Shares not being exempt from the registration
requirements of Section 5 of the Securities Act, other than general public disclosure that the Company has made in the past regarding the Company’s intentions to engage in an equity capital-raising transaction. 

4.18 Insurance. The Company maintains insurance underwritten by insurers of recognized financial responsibility, of the types and in
the amounts that the Company reasonably believes is adequate for its business, including, but not limited to, insurance covering all real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism and
all other risks customarily insured against, with such deductibles as are customary for companies in the same or similar business, all of which insurance is in full force and effect. 

4.19 Additional Information. The information contained in the following documents, which the Placement Agent has furnished to the
Purchaser, as of the dates thereof, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein in light of the circumstances in which they were
made not misleading, except for any restatement, correction, revision, or update thereto described in any subsequent SEC Filing: 
 (a) the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014; 

(b) the Company’s Definitive Proxy Statement for the Annual Meeting of stockholders held May 27, 2015 and the Special Meeting of
stockholders on August 26, 2015; 
 (c) the Company’s Quarterly Reports on Form 10-Q for the fiscal quarter ended
March 31, 2015, the fiscal quarter ended June 30, 2015 and the fiscal quarter ended September 30, 2015; 
 (d) the
Company’s Current Reports on Form 8-K filed with the Commission on January 27, 2015, February 3, 2015, February 5, 2015, April 29, 2015, May 29, 2015, June 15, 2015, July 7,
2015 (as amended on July 15, 2015 and September 16, 2015), July 17, 2015, August 26, 2015, October 2, 2015, and November 2, 2015; and 

(e) all other documents, if any, filed by the Company with the Commission since December 31, 2014 pursuant to the reporting requirements
of the Exchange Act. 

  
 9 

 4.20 SEC Filings. Each of the Company’s SEC Filings, and any document attached as an
exhibit thereto (the “Incorporated Documents”), at the time it became or becomes effective or was filed with the Commission, as the case may be, complied in all material respects with the requirements of the Exchange Act, as
applicable, and the rules and regulations of the Commission thereunder (the “Exchange Act Rules and Regulations” and, together with the Securities Act Rules and Regulations, the “Rules and Regulations”), except
for any restatement, correction, revision, or update thereto described in any subsequent SEC Filing. In the past 12 calendar months, the Company has filed all documents required to be filed by it prior to the date hereof with the Commission pursuant
to the reporting requirements of the Exchange Act in a timely manner. 
 4.21 Bad Actor. None of the Company nor any predecessor
entity, nor, to the Company’s Knowledge, any affiliated issuer, director, general partner, managing member, executive officer, other officer of the Company participating in the offering of the Shares, any beneficial owner of 20% or more of the
Company’s outstanding voting equity securities calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, a
“Company Covered Person” and, together, “Company Covered Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a
“Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether any Company Covered Person is subject to a
Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations set forth in Rule 506(e) under the Securities Act, and the Company has furnished to the Placement Agent a copy of any disclosures provided
thereunder. The Company will notify the Placement Agent in writing, prior to the Closing Date, if any, of any Disqualification Event relating to any Company Covered Person not previously disclosed to the Placement Agent in accordance with this
Section. 
 4.22 Price of Common Stock. The Company has not taken, and will not take, directly or indirectly, any action designed to
cause or result in, or that has constituted or that might reasonably be expected to constitute, the stabilization or manipulation of the price of the shares of the Common Stock to facilitate the sale or resale of the Shares. 

4.23 Non-Public Information. Other than any material, non-public information included in the Disclosure Materials, the Company
confirms that neither it nor any of its officers or directors nor any other person acting on its or their behalf has provided, and it has not authorized the Placement Agent to provide, the Purchaser or its respective agents or counsel with any
information that it believes constitutes or could reasonably be expected to constitute material, non-public information. On or before 9:00 a.m., New York City time, on the third business day after the date hereof, the Company shall file a Current
Report on Form 8-K disclosing all material, non-public information previously disclosed to the Purchaser, including, without limitation, all material, non-public information included in the Disclosure Materials and the material terms of the
transactions contemplated by this Agreement, and attaching as an exhibit to such Form 8-K a form of this Agreement (including such exhibit, the “8-K Filing”). From and after the filing of the 8-K Filing, the Purchaser shall not be
in possession of any material, non-public information received from the Company, any subsidiary or any of their respective officers, directors or employees or the Placement Agent. The Company shall not, and

  
 10 

 
shall use its best efforts to cause each of its officers, directors, employees and agents not to, provide the Purchaser with any material nonpublic information regarding the Company from and
after the filing of the 8-K Filing without the express written consent of the Placement Agent. The Company understands and confirms that the Purchaser will rely on the representations and covenants set forth in this section in effecting transactions
in securities of the Company. 
 4.24 Use of Purchaser Name. Except as otherwise required by applicable law or regulation, the
Company shall not use the Purchaser’s name or the name of any of its affiliates or investment advisers in any advertisement, announcement, press release or other similar public communication unless it has received the prior written consent of
the Purchaser for the specific use contemplated. 
 4.25 Related Party Transactions. No transaction has occurred between or among
the Company, on the one hand, and its affiliates, officers or directors on the other hand, that is required to have been described under applicable securities laws in its Exchange Act filings that are not so described in such filings. 

4.26 Off-Balance Sheet Arrangements. There is no transaction, arrangement or other relationship between the Company and an
unconsolidated or other off-balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings that is not so disclosed or that otherwise would be reasonably likely to have a Material Adverse Effect. There are no such
transactions, arrangements or other relationships with the Company that may create contingencies or liabilities that are required to be disclosed by the Company in its Exchange Act filings and are not otherwise disclosed by the Company in its
Exchange Act filings. 
 4.27 Governmental Permits, Etc. Except as disclosed in the Disclosure Materials, the Company and its
subsidiaries have all franchises, licenses, certificates and other authorizations from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company
as currently conducted, except where the failure to possess currently such franchises, licenses, certificates and other authorizations would not reasonably be expected to have a Material Adverse Effect. Except as disclosed in the Disclosure
Materials, neither the Company nor any subsidiary has received any notice of proceedings relating to the revocation or modification of any such permit that, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected
to have a Material Adverse Effect. 
 4.28 Financial Statements. The consolidated financial statements of the Company and the
related notes and schedules thereto included in its Exchange Act filings since December 31, 2014 (i) comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect
thereto as in effect at the time of filing and (ii) fairly present in all material respects the financial position, results of operations, stockholders’ equity and cash flows of the Company and its consolidated subsidiaries at the dates
and for the periods specified therein. Such financial statements and the related notes and schedules thereto have been prepared in accordance with generally accepted accounting principles consistently applied throughout the periods involved (except
as otherwise noted therein) and all adjustments necessary for a fair presentation of results for such periods have 

  
 11 

 
been made; provided, however, that the unaudited financial statements are subject to normal year-end audit adjustments (which are not expected to be material) and do not contain all footnotes
required under generally accepted accounting principles. 
 4.29 Home Owners’ Loan Act. The Company is duly registered as a
savings and loan holding company under the Home Owners’ Loan Act. The Company’s banking subsidiary, Sunshine Bank (the “Bank”), holds the requisite authority from the Office of the Comptroller of the Currency (the
“OCC”) to do business as a federal savings bank under the laws of the United States. The Company and the Bank are in compliance in all material respects with all laws, applicable to their respective business and assets,
administered by the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the Federal Deposit Insurance Corporation (the “FDIC”), the OCC and any other federal banking authorities (together
with the Federal Reserve Board, the OCC and the FDIC, the “Bank Regulatory Authorities”) with jurisdiction over the Company and its subsidiaries, except for failures to be so in compliance that would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. 
 4.30 Deposit Accounts. The Bank’s deposits (as defined
in 12 USC § 1813(l)) are insured up to the maximum amount provided by the FDIC and no proceedings for the modification, termination or revocation of any such insurance are pending or, to the Company’s Knowledge, threatened. 

4.31 No Restrictions on Subsidiaries. No Significant Subsidiary of the Company is currently prohibited, directly or indirectly, under
any order of the OCC, or any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such Significant Subsidiary’s capital stock, from repaying to the
Company any loans or advances to such Significant Subsidiary from the Company or from transferring any of such Significant Subsidiary’s properties or assets to the Company or any other subsidiary of the Company, other than restrictions referred
to in this Section which are applicable generally to federal savings banks and their affiliates. 
 4.32 Listing Compliance. The
Company is in material compliance with the requirements of the NASDAQ Capital Market (the “NASDAQ”) for continued listing of the Common Stock thereon. The Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or the listing of the Common Stock on the NASDAQ, nor has the Company received any notification that the Commission or the NASDAQ is contemplating terminating such registration
or listing. The transactions contemplated by the Agreements will not contravene in any material respect the rules and regulations of the NASDAQ. The Company will comply with all requirements of the NASDAQ with respect to the issuance of the Shares
and shall cause the Shares to be listed on the NASDAQ and listed on any other exchange on which the Company’s common stock is listed on or before the Closing Date. 

4.33 Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurances that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in

  
 12 

 
conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has disclosure controls and procedures
(as defined in Rules 13a-14 and 15d-14 under the Exchange Act) that are designed to ensure that material information relating to the Company is made known to the
Company’s principal executive officer and the Company’s principal financial officer or persons performing similar functions. The Company is otherwise in compliance in all material respects with all applicable provisions of the
Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated thereunder. 
 4.34 Foreign Corrupt Practices.
Neither the Company, nor any Significant Subsidiary, nor, to the Knowledge of the Company, any director, officer, agent, employee or other Person acting on behalf of the Company or any Significant Subsidiary has, in the course of its actions for, or
on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or
domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 
 4.35 ERISA. The Company
is in compliance in all material respects with all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (herein called
“ERISA”); no “reportable event” (as defined in ERISA), other than those events as to which the thirty-day notice period is waived, has occurred with respect to any “pension plan” (as defined in ERISA) for which
the Company would have any material liability; the Company has not incurred and does not reasonably expect to incur liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “pension plan”; or
(ii) Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the “Code”); and each “Pension Plan” for which the Company would have
liability that is intended to be qualified under Section 401(a) of the Code is so qualified in all material respects and nothing has occurred, whether by action or by failure to act, which would reasonably be expected to result in the loss
of such qualification. 
 4.36 Environmental Matters. There has been no material storage, disposal, generation, manufacture,
transportation, handling or treatment of toxic wastes, hazardous wastes or hazardous substances by the Company or to its Knowledge, any of its subsidiaries (or, to the Knowledge of the Company, any of their predecessors in interest) at, upon or from
any of the property now or previously owned or leased by the Company or any of its subsidiaries in material violation of any applicable law, ordinance, rule, regulation, order, judgment, decree or permit or that would require material remedial
action under any applicable law, ordinance, rule, regulation, order, judgment, decree or permit; there has been no material spill, discharge, leak, emission, injection, escape, dumping or release of any kind into such property or into the
environment surrounding such property of any toxic wastes, medical wastes, solid wastes, hazardous wastes or hazardous substances due to or caused by the Company or any 

  
 13 

 
of its subsidiaries or with respect to which the Company or any of its subsidiaries have Knowledge; the terms “hazardous wastes”, “toxic wastes”, “hazardous
substances”, and “medical wastes” shall have the meanings specified in any applicable local, state, federal and foreign laws or regulations with respect to environmental protection. 

4.37 Integration; Other Issuances of Shares. Neither the Company nor its subsidiaries or any affiliates, nor any Person acting on its
or their behalf, has issued any shares of Common Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common Stock which
would be integrated with the sale of the Shares to such Purchaser for purposes of the Securities Act or of any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated
quotation system on which any of the securities of the Company are listed or designated, nor will the Company or its subsidiaries or affiliates take any action or steps that would require registration of the Shares offered hereby under the
Securities Act or cause the offering of the Shares to be integrated with other securities offerings. Assuming the accuracy of the representations and warranties of Purchasers, the offer and sale of the Shares by the Company to the Purchasers
pursuant to this Agreement will be exempt from the registration requirements of the Securities Act. 
 4.38 Application of Takeover
Protections; Rights Agreements. The Company has not adopted any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change in control of the Company. The Company and its Board
have taken all action necessary to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s articles
of incorporation or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is or could become applicable to the Purchaser as a direct consequence of the transactions contemplated by this Agreement,
including, without limitation, the Company’s issuance of the Shares and the Purchaser’s ownership of the Shares. 
 4.39
OFAC. Neither the Company nor any subsidiary nor, to the Company’s Knowledge, any director, officer, agent, employee, affiliate or person acting on behalf of the Company or any subsidiary is currently subject to any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not knowingly, directly or indirectly, use the proceeds of the sale of the Shares, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, towards any sales or operations in any country sanctioned by OFAC or for the purpose of financing the activities of any person currently subject to any
U.S. sanctions administered by OFAC. 
 4.40 Money Laundering Laws. The operations of each of the Company and any subsidiary are and
have been conducted at all times in compliance with the money laundering statutes of applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
applicable governmental agency (collectively, the “Money Laundering Laws”) except for failures to be so in compliance that would not, individually or in the aggregate, reasonably be 

  
 14 

 
expected to have a Material Adverse Effect, and to the Company’s Knowledge, no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company and/or any subsidiary with respect to the Money Laundering Laws is pending or threatened. 
 4.41 Compliance with
Certain Banking Regulations. The Company has no Knowledge of any facts and circumstances that would cause Sunshine Bank, in any material respect: (i) to be deemed not to be in satisfactory compliance with the Community Reinvestment Act and
the regulations promulgated thereunder or to be assigned a CRA rating by federal or state banking regulators of lower than “satisfactory”; (ii) to be deemed to be operating in violation, in any material respect, of the Bank Secrecy
Act of 1970 (or otherwise known as the “Currency and Foreign Transactions Reporting Act”), the USA Patriot Act (or otherwise known as “Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct
Terrorism Act of 2001”), any order issued with respect to anti-money laundering by OFAC or any other anti-money laundering statute, rule or regulation; or (iii) to be deemed not to be in satisfactory compliance, in any material respect,
with all applicable privacy of customer information requirements contained in any federal and state privacy laws and regulations as well as the provisions of all information security programs adopted by Sunshine Bank. 

4.42 Reports, Registrations and Statements. Since January 1, 2014, the Company and each subsidiary have filed all material
reports, registrations and statements, together with any required amendments thereto, that it was required to file with the Bank Regulatory Authorities and any other applicable federal or state securities or banking authorities. All such reports and
statements filed with any such regulatory body or authority are collectively referred to herein as the “Company Reports.” As of their respective dates, the Company Reports complied in all material respects with all the rules and
regulations promulgated by the Bank Regulatory Authorities and any other applicable foreign, federal or state securities or banking authorities, as the case may be. 

4.43 Agreements with Regulatory Agencies. Neither the Company nor any subsidiary is subject to any cease-and-desist or other similar
order or enforcement action issued by, or is a party to any written agreement, consent agreement or memorandum of understanding with, or is a party to any commitment letter or similar undertaking to, or is subject to any capital directive by, or
since December 31, 2012, has adopted any board resolutions at the request of, any governmental entity that currently restricts in any material respect the conduct of its business or that in any material manner relates to its capital adequacy,
its liquidity and funding policies and practices, its ability to pay dividends, its credit, risk management or compliance policies, its internal controls, its management or its operations or business (each item in this sentence, a
“Regulatory Agreement”), nor has the Company or any subsidiary been advised since December 31, 2012 by any governmental entity that it is considering issuing, initiating, ordering, or requesting any such Regulatory Agreement.

 4.44 Shell Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1). 

  
 15 

 SECTION 5. Representations, Warranties and Covenants of the Purchaser. The Purchaser
represents and warrants to, and covenants with, the Company that: 
 5.1 Experience. (i) The Purchaser is knowledgeable,
sophisticated and experienced in financial and business matters, in making, and is qualified to make, decisions with respect to investments in shares representing an investment decision like that involved in the purchase of the Shares, including
investments in securities issued by the Company and comparable entities, has the ability to bear the economic risks of an investment in the Shares and has reviewed carefully the Disclosure Materials and has requested, received, reviewed and
considered all information it deems relevant in making an informed decision to purchase the Shares; (ii) the Purchaser is acquiring the number of Shares set forth on the signature page attached hereto in the ordinary course of its business and
for its own account for investment only and with no present intention of distributing any of such Shares or any arrangement or understanding with any other persons regarding the distribution of such Shares (this representation and warranty not
limiting the Purchaser’s right to sell pursuant to the Registration Statement or in compliance with the Securities Act and the Rules and Regulations, or, other than with respect to any claims arising out of a breach of this representation and
warranty, the Purchaser’s right to indemnification under Section 7.3); (iii) the Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise
acquire or take a pledge of) any of the Shares, nor will the Purchaser engage in any short sale that results in a disposition of any of the Shares by the Purchaser, except in compliance with the Securities Act and the Rules and Regulations and any
applicable state securities laws; (iv) the Purchaser has completed or caused to be completed the Registration Statement Questionnaire attached hereto as part of Appendix I, for use in preparation of the Registration Statement, and the
answers thereto are true and correct as of the date hereof and will be true and correct as of the effective date of the Registration Statement and the Purchaser will notify the Company immediately of any material change in any such information
provided in the Registration Statement Questionnaire until such time as the Purchaser has sold all of its Shares or until the Company is no longer required to keep the Registration Statement effective; (v) the Purchaser has, in connection with
its decision to purchase the number of Shares set forth on the signature page attached hereto, relied solely upon the Disclosure Materials, including the documents incorporated by reference therein, and the representations and warranties of the
Company contained herein has not relied on the Placement Agent or on any statements or other information provided by the Placement Agent concerning the Company or the terms of this offering; and (vi) the Purchaser has had an opportunity to
discuss this investment with representatives of the Company and ask questions of them. Notwithstanding the foregoing provisions of this paragraph or any other provision of this Agreement, the Purchaser is consummating the transactions contemplated
by this Agreement without any representation or warranty, expressed or implied, by the Company except as expressly set forth in this Agreement and the exhibits and schedules hereto. The Purchaser acknowledges and agrees that the Company does not
make and has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 4. 

5.2 Purchaser Status. The Purchaser is an “accredited investor” within the meaning of Rule 501(a) of Regulation D
promulgated under the Securities Act and an “institutional account” as defined in FINRA Rule 4512(c). 
 5.3 Reliance on
Exemptions. The Purchaser understands that the Shares are being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act, the Rules and Regulations and state securities laws and that

  
 16 

 
the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser
set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Shares. If any of the representations deemed to have been made by it by its purchase of the Shares are no longer accurate
prior to Closing, the Purchaser shall promptly notify the Company and the Placement Agent. If the Purchaser is acquiring the Shares as a fiduciary or agent for one or more investor accounts, it represents that it has sole investment discretion with
respect to each such account and it has full power to make the foregoing representations, acknowledgements and agreements on behalf of such account. The Company and the Placement Agent will be entitled to rely upon this Agreement and is irrevocably
authorized to produce this Agreement or a copy hereof to (i) any regulatory authority having jurisdiction over the Company and its Affiliates or the Placement Agent and (ii) any interested party in any administrative or legal proceeding or
official inquiry with respect to the matters covered hereby, in each case, to the extent required by any court or governmental entity to which the Company or the Placement Agent is subject, provided that the Company provides the Purchaser with prior
written notice of such disclosure to the extent practicable and allowed by applicable law. 
 5.4 No Reliance on Placement Agent.
The Purchaser acknowledges that the Placement Agent and its directors, officers, employees, representatives and controlling persons have no responsibility for making any independent investigation of the information contained in the Disclosure
Materials or the Company’s Exchange Act Filings and make no representation or warranty to the Purchaser, express or implied, with respect to the Company or the Shares or the accuracy, completeness or adequacy of the Disclosure Materials, the
Company’s Exchange Act Filings or any other publicly available information, nor shall any of the foregoing persons be liable for any loss or damages of any kind resulting from the use of the information contained therein or otherwise supplied
to the Purchaser. The Purchaser is purchasing the Shares directly from the Company and not from the Placement Agent. 
 5.5
[Intentionally Left Blank] 
 5.6 Investment Decision. The Purchaser understands that nothing in the Agreement or any other
materials presented to the Purchaser in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. The Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Shares. 
 5.7 Risk of Loss. The Purchaser understands that its
investment in the Shares involves a significant degree of risk, including a risk of total loss of the Purchaser’s investment, and the Purchaser has full cognizance of and understands all of the risk factors related to the Purchaser’s
purchase of the Shares, including, but not limited to, those set forth under the caption “Risk Factors” in the Disclosure Materials. The Purchaser understands that no representation is being made as to the future value or market price of
the Common Stock. 

  
 17 

 5.8 Legend. The Purchaser understands that, until such time as the Registration Statement
has been declared effective or the Shares may be sold pursuant to Rule 144 under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Shares will bear a
restrictive legend in substantially the following form: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS OF OTHER
JURISDICTIONS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER
APPLICABLE LAWS.” 
 5.9 Stop Transfer. The Purchaser understands that the certificates representing the Shares will be subject
to a stop transfer order with the Company’s transfer agent that restricts the transfer of such shares except upon receipt by the transfer agent of a written confirmation from the Purchaser to the effect that the Purchaser has satisfied its
prospectus delivery requirements, in the form attached as Exhibit A hereto. At such time as the Shares are no longer required to bear a restrictive legend, the Company agrees that it will, no later than five business days after delivery by
the Purchaser to the Company or its transfer agent of a certificate (in the case of a transfer, in the proper form for transfer) representing Shares issued with the foregoing restrictive legend, deliver or cause to be delivered to the Purchaser a
certificate representing such Shares that is free from all restrictive and other legends. 
 5.10 Residency. The Purchaser’s
principal executive offices are in the jurisdiction set forth immediately below the Purchaser’s name on the signature pages hereto. 

5.11 Public Sale or Distribution. The Purchaser hereby covenants with the Company not to make any sale of the Shares under the
Registration Statement without complying with the provisions of this Agreement and without effectively causing the prospectus delivery requirement under the Securities Act to be satisfied (whether physically or through compliance with Rule 172
under the Securities Act or any similar rule). The Purchaser acknowledges that there may occasionally be times when the Company must suspend the use of the prospectus (the “Prospectus”) forming a part of the Registration Statement
(a “Suspension”) until such time as an amendment to the Registration Statement has been filed by the Company and declared effective by the Commission, or until such time as the Company has filed an appropriate report with the
Commission pursuant to the Exchange Act. Without the Company’s prior written consent, which consent shall not unreasonably be withheld or delayed, the 

  
 18 

 
Purchaser shall not use any written materials to offer the Shares for resale other than the Prospectus, including any “free writing prospectus” as defined in Rule 405 under the
Securities Act. The Purchaser covenants that it will not sell any Shares pursuant to said Prospectus during the period commencing at the time when Company gives the Purchaser written notice of the suspension of the use of said Prospectus and ending
at the time when the Company gives the Purchaser written notice that the Purchaser may thereafter effect sales pursuant to said Prospectus. 

5.12 Organization; Validity; Enforcements. The Purchaser further represents and warrants to, and covenants with, the Company that
(i) the Purchaser has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this
Agreement, (ii) the making and performance of this Agreement by the Purchaser and the consummation of the transactions herein contemplated will not violate any provision of the organizational documents of the Purchaser or conflict with, result
in the breach or violation of, or constitute, either by itself or upon notice or the passage of time or both, a default under any material agreement, mortgage, deed of trust, lease, franchise, license, indenture, permit or other instrument to which
the Purchaser is a party or, any statute or any authorization, judgment, decree, order, rule or regulation of any court or any regulatory body, administrative agency or other governmental agency or body applicable to the Purchaser, (iii) no
consent, approval, authorization or other order of, or notice to, registration, declaration or filing with, exemption or review by, or expiration or termination of any statutory waiting period of, any court, regulatory body, administrative agency or
other governmental agency or body is required on the part of the Purchaser for the execution and delivery of this Agreement or the consummation of the transactions contemplated by this Agreement, including without limitation under the Home
Owners’ Loan Act, the CIBC Act or any rules or regulations promulgated thereunder (or any successor provisions) other than any passivity or anti-association commitments that are required by the Federal Reserve and which have been delivered to
the Federal Reserve, (iv) upon the execution and delivery of this Agreement, this Agreement shall constitute a legal, valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except as such enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application relating to or the enforcement of creditor’s rights and the application of equitable principles relating to the availability of
remedies, and except as rights to indemnity or contribution, including, but not limited to, the indemnification provisions set forth in Section 7.3 of this Agreement, may be limited by federal or state securities laws or the public policy
underlying such laws and (v) there is not in effect any order enjoining or restraining the Purchaser from entering into or engaging in any of the transactions contemplated by this Agreement. 

5.13 Short Sales. Prior to the time the Purchaser was first contacted by the Placement Agent, the Purchaser has not taken, and prior
to the public announcement of the transaction after the Closing the Purchaser shall not take, any action that has caused or will cause the Purchaser to have, directly or indirectly, sold or agreed to sell any shares of Common Stock, effected any
short sale, whether or not against the box, established any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act with respect to the Common Stock, granted any other right (including, without limitation, any
put or call option)) with respect to the Common Stock or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock. 

  
 19 

 5.14 No Group. Other than affiliates of the Purchaser who are Other Purchasers, the
Purchaser is not under common control with or acting in concert with any other person and is not part of a “group” within the meaning of Section 13(d)(3) of the Exchange Act and Rule 13d-5(b)(1) thereunder. 

5.15 Ownership. 
 (a)
As of the date of this Agreement, other than as set forth on its signature page hereto, the Purchaser is not the owner of record or the beneficial owner of shares of Common Stock or other equity, securities convertible into or exchangeable for
Common Stock, or any other equity or equity linked security of the Company or any Company Subsidiary. 
 (b) Assuming the accuracy of the
representations and warranties of the Company and the performance of the covenants and agreements of the Company contained herein, the purchase of Shares hereunder shall not cause the Purchaser, together with any other person whose beneficial
ownership of Company securities would be aggregated with the Purchaser’s beneficial ownership of Company securities for purposes of any bank regulation or law, to collectively be deemed to own, control or have the power to vote securities which
(assuming, for this purpose only, full conversion and/or exercise of such securities by the Purchaser) would represent more than 9.9% of the voting securities, or 25% of total equity, of the Company outstanding at the Closing. 

5.16 Home Owners’ Loan Act. The Purchaser is not a depository institution, and is not, and is not required to register as, a
savings and loan holding company under the Home Owners’ Loan Act or bank holding company under the Bank Holding Company Act.
 5.17
Not Deposits and Uninsured. The Purchaser understands that the Shares are not savings or deposit accounts or other obligations of the Bank or any other Company Subsidiary, and the Shares are not insured by the FDIC or any other governmental
entity. 
 5.18 OFAC and Anti-Money Laundering. The Purchaser understands, acknowledges, represents and agrees that (i) the
Purchaser is not the target of any sanction, regulation, or law promulgated by the OFAC, the Financial Crimes Enforcement Network or any other U.S. governmental entity (“U.S. Sanctions Laws”); (ii) the Purchaser is not owned by,
controlled by, under common control with, or acting on behalf of any person that is the target of U.S. Sanctions Laws; (iii) the Purchaser is not a “foreign shell bank” and is not acting on behalf of a “foreign shell bank” under
applicable anti-money laundering laws and regulations; (iv) the Purchaser’s entry into this Agreement or consummation of the transactions contemplated hereby will not contravene U.S. Sanctions Laws or applicable anti-money laundering laws or
regulations; (v) the Purchaser will promptly provide to any regulatory or law enforcement authority such information or 

  
 20 

 
documentation as may be required to comply with U.S. Sanctions Laws or applicable anti-money laundering laws or regulations; and (vi) the Company may provide to any regulatory or law
enforcement authority information or documentation regarding, or provided by, the Purchaser for the purposes of complying with U.S. Sanctions Laws or applicable anti-money laundering laws or regulations. 

SECTION 6. Survival of Agreements; Non-Survival of Company Representations and Warranties. Notwithstanding any investigation made by
any party to this Agreement or by the Placement Agent, all covenants and agreements made by the Company and the Purchaser herein and in the certificates for the Shares delivered pursuant hereto shall survive the execution of this Agreement, the
delivery to the Purchaser of the Shares being purchased and the payment therefor. Each Purchaser shall be responsible only for its own representations and warranties, agreements and covenants hereunder. The representations and warranties made by the
Company and the Purchaser herein and in the certificates for the Shares delivered pursuant hereto shall survive for a period of one year following the later of the execution of this Agreement, the delivery to the Purchaser of the Shares being
purchased and the payment therefor. 
 SECTION 7. Registration of the Shares and Compliance with the Securities Act. 

7.1 Registration Procedures and Expenses. The Company shall: 

(a) as soon as practicable, but in no event later than thirty days following the Closing Date (the “Filing Deadline”),
prepare and file with the Commission the Registration Statement on Form S-3 relating to the resale of the Shares by the Purchaser and the Other Purchasers from time to time on the NASDAQ or the facilities
of any national securities exchange on which the Common Stock is then traded or in privately-negotiated transactions; prior to filing, the Company shall provide the Purchaser an opportunity to review and comment on the disclosure regarding the
Purchaser; 
 (b) use its best efforts, subject to receipt of necessary information from the Purchasers, to cause the Commission to declare
the Registration Statement effective by the earlier of (i) 60 days or, if the Registration Statement is selected for review by the Commission, 120 days after the Closing Date and (ii) the
5th business day after the date the Company is notified (orally or in writing, whichever is earlier) by the Commission that the Registration Statement will not be reviewed or will not be subject
to further review (such earlier date, the “Effective Deadline”); 
 (c) promptly prepare and file with the Commission such
amendments and supplements to the Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement effective until the earliest of (i) two years after the effective date of the
Registration Statement, (ii) such time as all of the Shares have been sold pursuant to the Registration Statement, or (iii) such time as the Shares become eligible for resale by a Purchaser without any volume limitations or other
restrictions pursuant to Rule 144(b)(1)(i) under the Securities Act or any other rule of similar effect; 

  
 21 

 (d) furnish to the Purchaser with respect to the Shares registered under the Registration
Statement (and to each underwriter, if any, of such Shares) such number of copies of prospectuses and such other documents as the Purchaser may reasonably request, in order to facilitate the public sale or other disposition of all or any of the
Shares by the Purchaser; 
 (e) bear all expenses in connection with the procedures in paragraphs (a) through (e) of this
Section 7.1 and the registration of the Shares pursuant to the Registration Statement, other than fees and expenses, if any, of counsel or other advisers to the Purchaser or the Other Purchasers or underwriting discounts, brokerage fees and
commissions incurred by the Purchaser or the Other Purchasers, if any, in connection with the offering of the Shares pursuant to the Registration Statement; 

(f) file a Form D with respect to the Shares as required under Regulation D and to provide a copy thereof to the Purchaser promptly
after filing; and 
 (g) in order to enable the Purchasers to sell the Shares under Rule 144 to the Securities Act, for a period of
one year from Closing, use its commercially reasonable efforts to comply with the requirements of Rule 144, including without limitation, use its commercially reasonable efforts to comply with the requirements of Rule 144(c)(1) with
respect to public information about the Company and to timely file all reports required to be filed by the Company under the Exchange Act. 

The Company understands that the Purchaser disclaims being an underwriter. A draft of the proposed form of the questionnaire related to the
Registration Statement to be completed by the Purchaser is attached hereto as Appendix I. 
 7.2 Transfer of Securities After
Registration. The Purchaser agrees that it will not effect any disposition of the Shares or its right to purchase the Shares that would constitute a sale within the meaning of the Securities Act or pursuant to any applicable state securities
laws, except as contemplated in the Registration Statement referred to in Section 7.1 or as otherwise permitted by law. 
 7.3
Indemnification. For the purpose of this Section 7.3: 
 (i) the term “Purchaser/Affiliate” shall mean any
affiliate of the Purchaser, including, without limitation, any general partner or managing member of the Purchaser, any investment adviser of the Purchaser, or any transferee who is an affiliate of the Purchaser, and any person who controls the
Purchaser or any affiliate of the Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act; and 

(ii) the term “Registration Statement” shall include any preliminary prospectus, final prospectus, free writing prospectus,
exhibit, supplement or amendment included in or relating to, and any document incorporated by reference in, the Registration Statement referred to in Section 7.1. 

  
 22 

 (a) The Company agrees to indemnify and hold harmless the Purchaser and each
Purchaser/Affiliate, against any out-of-pocket losses, claims, damages, liabilities or expenses, joint or several, that the Purchaser or Purchaser/Affiliate incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory
law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses (or actions in
respect thereof as contemplated below) (i) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, including the Prospectus, financial statements and
schedules, and all other documents filed as a part thereof, as amended at the time of effectiveness of the Registration Statement, including any information deemed to be a part thereof as of the time of effectiveness pursuant to paragraph
(b) of Rule 430A, or pursuant to Rules 430B, 430C or 434, of the Rules and Regulations, or the Prospectus, in the form first filed with the Commission pursuant to Rule 424(b) of the Regulations, or filed as part of the
Registration Statement at the time of effectiveness if no Rule 424(b) filing is required or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state in any of them a material fact
required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in light of the
circumstances under which they were made or (ii) arise out of or are based in whole or in part on any inaccuracy in the representations or warranties of the Company contained in this Agreement, or any failure of the Company to perform its
obligations hereunder or under law, and will promptly reimburse each Purchaser and each Purchaser/Affiliate for any legal and other out-of-pocket expenses reasonably incurred and documented by such Purchaser or such Purchaser/Affiliate in connection
with investigating, defending or preparing to defend, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the Company will not be liable for amounts paid in settlement of
any such loss, claim, damage, liability or action if such settlement is effected without the written consent of the Company, which consent shall not be unreasonably withheld, and the Company will not be liable in any such case to the extent that any
such loss, claim, damage, liability or expense arises out of or is based upon (i) the gross negligence or willful misconduct of such Purchaser, or (ii) an untrue statement or alleged untrue statement or omission or alleged omission made in
the Registration Statement, the Prospectus or any amendment or supplement thereto in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Purchaser expressly for use therein, or (iii) the
failure of such Purchaser to comply with the covenants and agreements contained in Sections 5.11 or 7.2 hereof respecting the sale of the Shares, or (iv) the inaccuracy of any representation or warranty made by such Purchaser herein or
(v) any statement or omission in any Prospectus that is corrected in any subsequent Prospectus that was delivered to the Purchaser prior to the pertinent sale or sales by the Purchaser. Any such indemnified Purchaser shall return all payments
made hereunder if it is determined, by a final, non-appealable judgment by a court or arbitral tribunal that the losses for which such payments were made resulted from such Indemnified Person’s gross negligence or willful misconduct. 

(b) Each Purchaser will severally, but not jointly, indemnify and hold harmless the Company, each of its directors, each of its officers who
signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, claims, damages,

  
 23 

 
liabilities or expenses that the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person incurs, under the Securities Act, the Exchange
Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, but only if such settlement is effected with the written consent of such Purchaser) insofar as such losses,
claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon (i) any failure to comply with the covenants and agreements contained in Sections 5.11 or 7.2 hereof respecting the
sale of the Shares or (ii) the inaccuracy of any representation or warranty made by such Purchaser herein or (iii) any untrue or alleged untrue statement of any material fact contained in the Registration Statement, the Prospectus, or any
amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or
supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in the light of the circumstances under which they were made, in each case to the extent, but only to the extent, that such untrue statement
or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the Company by or on
behalf of any Purchaser expressly for use therein; and will reimburse the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person for any legal and other expense reasonably incurred by the
Company, each of its directors, each of its officers who signed the Registration Statement or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or
action; provided, however, that each Purchaser’s aggregate liability under this Section 7 shall not exceed the amount of proceeds received by such Purchaser on the sale of the Shares pursuant to the Registration Statement. 

(c) Promptly after receipt by an indemnified party under this Section 7.3 of notice of the threat or commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 7.3 promptly notify the indemnifying party in writing thereof, but the omission to notify the indemnifying party will not
relieve it from any liability that it may have to any indemnified party for contribution or otherwise under the indemnity agreement contained in this Section 7.3 to the extent it is not prejudiced as a result of such failure. In case any such
action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it may wish, jointly with
all other indemnifying parties similarly notified, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified
party, and the indemnifying party and the indemnified party shall have reasonably concluded, based on an opinion of counsel reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the positions of the
indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties that are different from or additional to those available to the
indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon
receipt of notice from the indemnifying party to such indemnified party of its election to assume the defense of such action and approval 

  
 24 

 
by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section 7.3 for any legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed such counsel in connection with the assumption of legal defenses in accordance with the proviso to the preceding sentence (it being
understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such indemnifying party, representing all of the indemnified parties who are parties to such action)
or (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of action, in each of which cases the
reasonable fees and expenses of counsel shall be at the expense of the indemnifying party. In no event shall any indemnifying party be liable in respect of any amounts paid in settlement of any action unless the indemnifying party shall have
approved in writing the terms of such settlement; provided that such consent shall not be unreasonably withheld. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or
threatened proceeding in respect of which any indemnified party is or could have been a party and indemnification could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such
indemnified party from all liability on claims that are the subject matter of such proceeding. 
 (d) If the indemnification provided for
in this Section 7.3 is required by its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c) of this Section 7.3 in respect to any
losses, claims, damages, liabilities or expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses
referred to herein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Purchaser from the private placement of Shares hereunder or (ii) if the allocation provided by clause
(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but the relative fault of the Company and the Purchaser in connection with the
statements or omissions or inaccuracies in the representations and warranties in this Agreement and/or the Registration Statement that resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and each Purchaser on the other shall be deemed to be in the same proportion as the amount paid by such Purchaser to the Company pursuant to this Agreement for the Shares
purchased by such Purchaser that were sold pursuant to the Registration Statement bears to the difference (the “Difference”) between the amount such Purchaser paid for the Shares that were sold pursuant to the Registration Statement
and the amount received by such Purchaser from such sale. The relative fault of the Company on the one hand and each Purchaser on the other shall be determined by reference to, among other things, whether the untrue or alleged statement of a
material fact or the omission or alleged omission to state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to information supplied by the Company or by such Purchaser and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in paragraph (c) of this Section 7.3, 

  
 25 

 
any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in paragraph (c) of this
Section 7.3 with respect to the notice of the threat or commencement of any threat or action shall apply if a claim for contribution is to be made under this paragraph (d); provided, however, that no additional notice shall be
required with respect to any threat or action for which notice has been given under paragraph (c) for purposes of indemnification. The Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to this
Section 7.3 were determined solely by pro rata allocation (even if the Purchaser were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this
paragraph. Notwithstanding the provisions of this Section 7.3, no Purchaser shall be required to contribute any amount in excess of the amount by which the Difference exceeds the amount of any damages that such Purchaser has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The Purchasers’ obligations to contribute pursuant to this Section 7.3 are several and not joint. 

7.4 Termination of Conditions and Obligations. The restrictions imposed by Section 5.11 or Section 7.2 upon the
transferability of the Shares shall cease and terminate as to any particular number of the Shares upon the earlier of (i) the passage of two years from the effective date of the Registration Statement covering such Shares, (ii) at such
time as an opinion of counsel satisfactory in form and substance to the Company shall have been rendered to the effect that such conditions are not necessary in order to comply with the Securities Act, and (iii) at such time as the Shares
become eligible for resale by the Purchaser without any volume limitations or other restrictions pursuant to Rule 144(b)(1)(i) under the Securities Act or any other rule of similar effect. 

7.5 Information Available. Prior to Closing, the Company, upon the reasonable request of the Purchaser, shall make available for
inspection by each Purchaser, any deemed underwriter participating in any disposition pursuant to the Registration Statement and any attorney, accountant or other agent retained by the Purchaser or any deemed underwriter, all financial and other
records, pertinent corporate documents and properties of the Company. 
 7.6 Delay in Filing or Effectiveness of Registration
Statement If the Registration Statement is not filed by the Company with the Commission on or prior to the Filing Deadline, then for each day following the Filing Deadline, until but excluding the date the Registration Statement is filed, or if
the Registration Statement is not declared effective by the Commission by the Effective Deadline, then for each day following the Effective Deadline, until but excluding the date the Commission declares the Registration Statement effective, the
Company shall, for each such day, pay the Purchaser with respect to any such failure, as liquidated damages and not as a penalty, an amount per 30-day period equal to 1.0% of the purchase price paid by such
Purchaser for its Shares pursuant to this Agreement (calculated on a daily pro rata basis for any portion of such 30-day period prior to the cure of such failure); and for any such 30-day period (or earlier period if such failure is cured prior to
30 days), such payment shall be made no later than three business days following such 30-day period (or earlier period if such failure is cured prior to 30 days). If the Purchaser shall be prohibited from selling

  
 26 

 
Shares under the Registration Statement as a result of a Suspension of more than thirty (30) days or Suspensions on more than two (2) occasions of not more than thirty (30) days
each in any 12-month period, then for each day on which a Suspension is in effect that exceeds the maximum allowed period for a Suspension or Suspensions, but not including any day on which a Suspension is
lifted, the Company shall pay the Purchaser, as liquidated damages and not as a penalty, an amount per 30-day period equal to 1.0% of the purchase price paid by such Purchaser for its Shares pursuant to this Agreement for each such day (calculated
on a daily pro rata basis for any portion of such 30-day period prior to the cure of such event), and such payment shall be made no later than the first business day of the calendar month next succeeding the month in which such day occurs. For
purposes of this Section 7.6, a Suspension shall be deemed lifted on the date that notice that the Suspension has been lifted is delivered to the Purchaser pursuant to Section 5.11 of this Agreement. Any payments made pursuant to this
Section 7.6 shall constitute the Purchaser’s exclusive remedy for such events. Notwithstanding the foregoing provisions, in no event shall the Company be obligated to pay any liquidated damages pursuant to this Section 7.6 (i) to
more than one Purchaser in respect of the same Shares for the same period of time or (ii) in an aggregate amount that exceeds 10% of the purchase price paid by the Purchasers for the Shares pursuant to this Agreement. Such payments shall be
made to the Purchasers in cash. 
 SECTION 8. Broker’s Fee. The Purchaser acknowledges that the Company intends to pay to the
Placement Agent a fee in respect of the sale of the Shares to the Purchaser. The Purchaser and the Company agree that the Purchaser shall not be responsible for such fee and that the Company will indemnify and hold harmless the Purchaser and each
Purchaser/Affiliate against any losses, claims, damages, liabilities or expenses, joint or several, that such Purchaser or Purchaser/Affiliate incurs with respect to such fee. Each of the parties hereto represents that, on the basis of any actions
and agreements by it, there are no other brokers or finders entitled to compensation in connection with the sale of the Shares to the Purchaser. 

SECTION 9. Independent Nature of Purchasers’ Obligations and Rights. The obligations of the Purchaser under this Agreement are
several and not joint with the obligations of any Other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any Other Purchaser under the Agreements. The decision of each Purchaser to purchase the
Shares pursuant to the Agreements has been made by such Purchaser independently of any other Purchaser. Nothing contained in the Agreements, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Agreements.
Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment
in the Shares or enforcing its rights under this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for
any other Purchaser to be joined as an additional party in any proceeding for such purpose. 
 SECTION 10. Notices. All notices,
requests, consents and other communications hereunder shall be in writing, shall be mailed by first-class registered or 

  
 27 

 
certified airmail, e-mail, confirmed facsimile or nationally recognized overnight express courier postage prepaid, and shall be deemed given when so mailed and shall be delivered as addressed as
follows: 
 (a) if to the Company, to: 

Sunshine Bancorp, Inc. 
 102
West Baker Street 
 Plant City, Florida 33563 

Attention: Andrew Samuel 

E-mail: a.samuel@mysunshinebank.com 

with a copy to: 

Foley & Lardner LLP 

100 North Tampa Street Suite 2700 

Tampa, FL 33602-5810 

Attention: Martin Traber 

E-mail: mtraber@foley.com 
 or to
such other person at such other place as the Company shall designate to the Purchaser in writing; and 
 (b) if to the
Purchaser, at its address as set forth at the end of this Agreement, or at such other address or addresses as may have been furnished to the Company in writing. 

SECTION 11. Changes. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company
and the Purchaser. Any amendment or waiver effected in accordance with this Section 11 shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding, each future holder of all such securities, and
the Company. 
 SECTION 12. Headings. The headings of the various sections of this Agreement have been inserted for convenience of
reference only and shall not be deemed to be part of this Agreement. 
 SECTION 13. Severability. The invalidity or unenforceability
of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, each of which shall remain in full force and effect and in lieu of such invalid or unenforceable provision there shall be
automatically added as part of this Agreement a valid and enforceable provision as similar in terms to the invalid or unenforceable provision as possible, provided that this Agreement as amended, (i) reflects the intent of the parties hereto,
and (ii) does not change the bargained for consideration or benefits to be received by each party hereto. 
 SECTION 14. Governing
Law; Venue. This Agreement is to be construed in accordance with and governed by the federal law of the United States of America and the 

  
 28 

 
internal laws of the State of New York without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State
of New York to the rights and duties of the parties. Each of the Company and the Purchaser submits to the nonexclusive jurisdiction of the United States District Court for the Southern District of New York and of any New York State court sitting in
New York City for purposes of all legal proceedings arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the Company and the Purchaser irrevocably waives, to the fullest extent permitted by law, any
objection that it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that any such proceeding brought in such a court has been brought in an inconvenient forum. 

SECTION 15. Counterparts. This Agreement may be executed in counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. Facsimile signatures (including electronically
scanned copies of original signatures) shall be deemed original signatures. 
 SECTION 16. Entire Agreement. This Agreement and the
instruments referenced herein, and, until the terms of this Agreement are publicly disclosed by the Company, the confidentiality agreement by the Purchaser for the benefit of the Company and the Placement Agent, contain the entire understanding of
the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Purchaser makes any representation, warranty, covenant or undertaking with respect to such
matters. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement. 

SECTION 17. Fees and Expenses. Except as set forth herein, each of the Company and the Purchaser shall pay its respective fees and
expenses related to the transactions contemplated by this Agreement. 
 SECTION 18. Parties. This Agreement is made solely for the
benefit of and is binding upon the Purchaser and the Company and to the extent provided in Section 7.3, any person entitled to indemnification thereunder, and their respective executors, administrators, successors and assigns and, subject to
the provisions of Section 7.3, no other person shall acquire or have any right under or by virtue of this Agreement. The term “successor and assigns” shall not include any subsequent purchaser, as such purchaser, of the Shares sold to
the Purchaser pursuant to this Agreement. 
 SECTION 19. Further Assurances. Each party agrees to cooperate fully with the other
parties and to execute such further instruments, documents and agreements and to give such further written assurance as may be reasonably requested by any other party to evidence and reflect the transactions described herein and contemplated hereby
and to carry into effect the intents and purposes of this Agreement. 
 SECTION 20. Third-Party Beneficiary. The Company and the
Purchaser each agrees that the Placement Agent shall be, and is hereby, named as an express third-party 

  
 29 

 
beneficiary of this Agreement solely with respect to the representations and warranties of the Company and the Purchaser contained in Section 4 and Section 5, respectively, with full
rights as such. 
 SECTION 21. No Change of Control. The Company shall use reasonable best efforts to obtain all necessary
irrevocable waivers, adopt any required amendments and make all appropriate determinations so that the issuance of the Shares to the Purchasers will not trigger a “change of control” or other similar provision in any of the agreements to
which the Company or any of its subsidiaries is a party, including without limitation any employment, “change in control,” severance or other agreements and any benefit plan, which results in payments to the counterparty or the
acceleration of vesting of benefits. 
 SECTION 22. Avoidance of Control. Notwithstanding anything to the contrary in this
Agreement, neither the Company nor any subsidiary shall take any action (including, without limitation, any redemption, repurchase, rescission or recapitalization of Common Stock, or securities or rights, options or warrants to purchase Common
Stock, or securities of any type whatsoever that are, or may become, convertible into or exchangeable into or exercisable for Common Stock in each case, except where the Purchaser is given the right to participate in such redemption, repurchase,
rescission or recapitalization to the extent of the Purchaser’s pro rata proportion), that would cause the Purchaser’s ownership of any class of voting securities of the Company (together with the ownership by such Purchaser’s
affiliates (as such term is used under the Home Owners’ Loan Act) of voting securities of the Company) to exceed 9.9%, or 25% of the total equity, without the prior written consent of the Purchaser, or to increase to an amount that would
constitute “control” under the Home Owners’ Loan Act, the CIBC Act or any rules or regulations promulgated thereunder (or any successor provisions) or otherwise cause the Purchaser to “control” the Company under and for
purposes of the Home Owners’ Loan Act, the CIBC Act or any rules or regulations promulgated thereunder (or any successor provisions). It shall not constitute a default by the Company under this Section for the Company to record any such
transactions on its corporate records, or to take any actions required by any Bank Regulatory Authority. Notwithstanding anything to the contrary in this Agreement, no Purchaser (together with its affiliates (as such term is used under the Home
Owners’ Loan Act)) shall have the ability to purchase more than 9.9% of the total outstanding voting securities of the Company, or 25% of the total outstanding equity of the Company. In the event either the Company or the Purchaser breaches its
obligations under this Section 22 or believes that it is reasonably likely to breach such an obligation, it shall promptly notify the other party hereto and shall cooperate in good faith with such party to modify ownership or make other
arrangements or take any other action, in each case, as is necessary to cure or avoid such breach. 
 SECTION 23. Termination. This
Agreement may be terminated and the sale and purchase of the Shares abandoned at any time prior to the Closing by either the Company or the Purchaser upon written notice to the other, if the Closing has not been consummated on or prior to 5:00 p.m.,
New York City time, on the thirtieth (30th) day following the date of this Agreement; provided that if such day is not a business day, the first day following such day that is a business day;
provided, however, that the right to terminate this Agreement under this Section 23 shall not be available to any person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure
of the Closing to occur on or before such time. Nothing in this Section 23 shall be deemed to release any party from any liability for 

  
 30 

 
any breach by such party of the terms and provisions of this Agreement or to impair the right of any party to compel specific performance by any other party of its obligations under this
Agreement. In the event of a termination pursuant to this Section, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance with this Section, the Company and the Purchaser shall not have any further
obligation or liability (including arising from such termination) to the other. 

  
 31 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives as of the day and year first above written. 
  

					
	SUNSHINE BANCORP, INC.
		
	By:	 	 /s/ Andrew S. Samuel

		 	Name:	 	Andrew S. Samuel
		 	Title:	 	President and Chief Executive Officer

 [Company Signature Page to Purchase Agreement] 

							
		 	Print or Type:	 	
			
		 		 	  

		 		 	 Name of Purchaser
 (Individual or
Institution)

			
		 		 	  

		 		 	Jurisdiction of Purchaser’s Executive Offices
			
		 		 	  

		 		 	Name of Individual representing Purchaser (if an Institution)
			
		 		 	  

		 		 	Title of Individual representing Purchaser (if an Institution)
			
		 	Signature by:	 	
			
		 		 	Individual Purchaser or Individual representing Purchaser:
			
		 		 	  

				
		 		 	Address:	 	  

				
		 		 	Telephone:	 	  

				
		 		 	Facsimile:	 	  

				
		 		 	E-mail:	 	  

		
	Number of shares of Common Stock currently owned:	 	  

  

									
	 Number of Shares to Be Purchased
	  	Price Per
Share in Dollars	 	  	Aggregate
Price	 
		  	$	            	  	  	$	            	  
		  				  			
		  				  			
		  				  			
		  				  			

 EXHIBIT A 

LETTER TO TRANSFER AGENT— 

DELIVERABLE TO TROUTMAN SANDERS LLP AT CLOSING 

                 , 2015 

Computershare Inc. 
 250 Royall Street 

Canton, MA 02021 
 Attention:
                     
 Re: Sunshine Bancorp, Inc. (
the “Company”) PIPE Transaction 
 Dear Ladies and Gentlemen: 

                    , a purchaser in the
Sunshine Bancorp, Inc. PIPE transaction, understands: (i) that the shares of common stock were offered and sold in reliance upon specific exemptions from the registration requirements of the Securities Act of 1933, as amended (the
“Securities Act”), and (ii) that the Company is relying on the truth and accuracy of, and compliance by each purchaser with, the representations, warranties, agreements, acknowledgements and understandings made by the purchaser
pursuant to Section 5 of that certain Purchase Agreement, dated on or about                  , 2015 (the “Purchase Agreement”) as executed by the
Company and the purchaser. 
 In connection therewith, we hereby covenant with the Company not to make any sale of the shares without
complying in all material respects with the provisions of the Purchase Agreement and without effectively causing the prospectus delivery requirement under the Securities Act to be satisfied. We agree with the Company that the shares will be
transferable only upon the delivery to the transfer agent of the Purchaser’s Certificate of Subsequent Sale pursuant to the Registration Statement (included as an appendix to the Purchase Agreement). We acknowledge receipt of the shares, free
of restrictive legend, in recognition of the fact that a registration statement relating to their resale by us from time to time has been declared effective, subject to these limitations on transferability. We further understand that you will be
relying on our representations and covenants made in the Purchase Agreement and in this letter. 
  

			
	Sincerely,
		
	By:	 	  

		 	Name:
		 	Title:

  
 A-1 

 EXHIBIT B 

SIGNIFICANT SUBSIDIARIES 
  

			
	 Subsidiary
	  	Jurisdiction of
Incorporation
	Sunshine Bank	  	United States

  
 B-1 

 APPENDIX I 

SUMMARY INSTRUCTION SHEET FOR PURCHASER 

(to be read in conjunction with the entire Purchase Agreement which follows) 

A. Complete the following items on the Purchase Agreement (Please sign two originals): 

 

	 	1.	Signature Page: 

  

	 	(i)	Name of Purchaser (Individual or Institution) 

  

	 	(ii)	Name of Individual representing Purchaser (if an Institution) 

  

	 	(iii)	Title of Individual representing Purchaser (if an Institution) 

  

	 	(iv)	Signature of Individual Purchaser or Individual representing Purchaser 

  

	 	2.	Appendix I - Securities Certificate Questionnaire/Registration Statement Questionnaire: 

Provide the information requested by the Securities Certificate Questionnaire and the Registration Statement Questionnaire. 

 

	 	3.	Return the properly completed and signed Purchase Agreement including the properly completed Appendix I to (initially by facsimile or email with original by overnight delivery): 

Raymond James & Associates 

Financial Services Group ECM 

222 South Riverside Plaza, 
 7th Floor 
 Chicago, IL 60606 

Attention: Douglas F. Secord 

Email: doug.secord@raymondjames.com 
 B.
Instructions regarding the transfer of funds for the purchase of Shares will be sent by facsimile to the Purchaser by the Placement Agent. 
 C. Upon the
resale of the Shares by the Purchasers after the Registration Statement covering the Shares is effective, as described in the Purchase Agreement, the Purchaser must deliver a current prospectus of the Company to the buyer (prospectuses must be
obtained from the Company at the Purchaser’s request). 

 SUNSHINE BANCORP, INC. 

SECURITIES CERTIFICATE QUESTIONNAIRE 

Pursuant to Section 3 of the Agreement, please provide us with the following information: 

 

					
	1.	 	The exact name that your Shares are to be registered in (this is the name that will appear on your stock certificate(s)). You may use a nominee name if appropriate:	 	  

			
	2.	 	The relationship between the Purchaser of the Shares and the Registered Holder listed in response to item 1 above:	 	  

			
	3.	 	The mailing address of the Registered Holder listed in response to item 1 above:	 	  

		 		 	  

		 		 	  

		 		 	  

			
	4.	 	The Social Security Number or Tax Identification Number of the Registered Holder listed in response to item 1 above:	 	  

 SUNSHINE BANCORP, INC. 

REGISTRATION STATEMENT QUESTIONNAIRE 

In connection with the preparation of the Registration Statement, please provide us with the following information: 

SECTION 1. Pursuant to the “Selling Stockholder” section of the Registration Statement, please state your or your
organization’s name exactly as it should appear in the Registration Statement: 
  

 
  

 
 SECTION 2. Please provide the number
of shares of Common Stock of the Company that you or your organization will own immediately after Closing, including those Shares purchased by you or your organization pursuant to this Purchase Agreement and those shares purchased by you or your
organization through other transactions and provide the number of shares that you have or your organization has the right to acquire within 60 days of Closing: 
  

 
  

 
 SECTION 3. Have you or your
organization had any position, office or other material relationship within the past three years with the Company or its affiliates? 

         Yes             No

 If yes, please indicate the nature of any such relationships below: 

 
  
  

 
  

 
  

 

 SECTION 4. Are you (a) (i) a FINRA Member (see definition), (ii) a Controlling
(see definition) shareholder of a FINRA Member, (iii) a Person Associated with a Member of the FINRA (see definition), or (iv) an Underwriter or a Related Person (see definition) with respect to the proposed offering; or (b) do you
own any shares or other securities of any FINRA Member not purchased in the open market; or (c) have you made any outstanding subordinated loans to any FINRA Member? 

Answer:  ̈ Yes     ̈ No If
“yes,” please describe below: 
  
  

 
  
  

 
  

 

 FINRA Member. The term “FINRA Member” means either any broker or dealer admitted
to membership in the Financial Industry Regulatory Authority (formerly, the National Association of Securities Dealers, Inc., “FINRA”). (FINRA Manual, By-laws of FINRA Regulation, Inc. Article I, Definitions) 

Control. The term “control” (including the terms “controlling,” “controlled by” and “under common
control with”) means the possession, direct or indirect, of the power, either individually or with others, to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by
contract, or otherwise. (Rule 405 under the Securities Act of 1933, as amended) 
 Person Associated with a member of the FINRA.
The term “person associated with a member of the FINRA” means every sole proprietor, partner, officer, director, branch manager or executive representative of any FINRA Member, or any natural person occupying a similar status or performing
similar functions, or any natural person engaged in the investment banking or securities business who is directly or indirectly controlling or controlled by a FINRA Member, whether or not such person is registered or exempt from registration with
the FINRA pursuant to its bylaws. (FINRA Manual, By-laws of FINRA Regulation, Inc. Article I, Definitions) 
 Underwriter or a Related
Person. The term “underwriter or a related person” means, with respect to a proposed offering, underwriters, underwriters’ counsel, financial consultants and advisors, finders, members of the selling or distribution group, and any
and all other persons associated with or related to any of such persons. (FINRA Interpretation) 

 Schedule 4.3 

Additional Disclosure 
 Authorized and Issued
Shares: 
 50,000,000 shares of authorized Common Stock, par value $0.01 per share, of which 4,391,124 shares are outstanding as of the date of this
Agreement. 
 5,000,000 shares of authorized Preferred Stock, par value $0.01 per share, none of which are outstanding as of the date of this Agreement.

 As of the date of this Agreement, the Company has outstanding options to purchase an aggregate of 373,758 shares of its Common Stock.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]